Cell-based therapy after myocardial infarction (MI) is a promising therapeutic option but the relevant cell subsets and dosage requirements are poorly defined. We hypothesized that cell therapy for myocardial infarction is improved by ex vivo expansion and high-dose transplantation of defined hematopoietic progenitor cells (HPCs). Since β-catenin promotes self-renewal of stem cells we evaluated the therapeutic efficacy of β-catenin-mediated ex vivo expansion of mouse HPCs in a mouse model of myocardial ischemia/ reperfusion followed by intraarterial cell delivery. The impact of cell dose was determined by comparing a low-dose (LD, 5 × 10 5 cells) vs. a high-dose (HD, 1 × 10 7 cells) cell transplantation regimen of β-catenin-HPCs.
Introduction
A leading cause of heart failure is myocardial ischemia, which precipitates dysfunction and death of cardiomyocytes [1] . The primary cardiac response to myocardial infarction (MI) is characterized by cardiomyocyte hypertrophy, apoptotic myocyte loss, progressive collagen replacement, and enlargement of the left ventricle [2, 3] .
Cell transplantation is considered to represent a novel and promising therapeutic option to support endogenous regenerative mechanisms in ischemic heart disease and heart failure [4, 5] . Recent studies suggest that bone marrow stem cells (BMCs) [6] [7] [8] [9] and hematopoietic progenitor cells (HPCs) [10, 11] are useful in cell transplantation after MI. However, due to the heterogeneous nature of the used cell populations the most efficient cell type and required cell dose is currently unclear, and recent clinical trials have reported conflicting outcomes [7, 8, 12] . Furthermore, the relatively low number of progenitor cells and the difficulties of ex vivo expansion represent a major practical limitation. Therefore, genetic modification of stem cells might be an option to overcome these limitations in cell-based therapeutic applications.
Wnt signaling promotes self-renewal of hematopoietic side populations, neuronal precursor cells, and embryonic stem cells [13] [14] [15] . Using retroviral β-catenin gene transfer we recently generated a multipotent mouse HPC line with a lin − /Sca-1 + /c-kit + phenotype (β-catenin-HPCs) [16] . This cell line does not express pan surface markers of myeloid, erythroid or lymphoid lineages, reconstitutes all hematopoietic lineages without leukemogenic transformation in vivo and displays unlimited expansion potential in vitro. We hypothesized that cell therapy for myocardial infarction requires a critically high cell number, which can be met using ex vivo expansion of HPC. While recent studies combined models of permanent coronary occlusion with intramyocardial delivery of stem cells [4, 17, 18] , established clinical practice mandates early coronary reperfusion post infarction followed by stem cell therapy. Accordingly, we established a mouse model of temporary coronary occlusion followed by reperfusion and intraarterial cell application into the ascending aorta. We show that administration of defined β-cateninHPCs after MI reduces infarct size and improves left ventricle (LV) function and dimensions in a threshold-dependent manner. This effect is associated with improved angiogenesis and reduced apoptosis in the infarct border zone. Furthermore, β-catenin-HPCs have greater therapeutic efficacy than control-transduced HPCs, demonstrating a beneficial effect of β-catenin transduction on myocardial repair.
Methods

Cell isolation and retroviral gene transfer
Isolation of HPCs was performed as described previously [19] . In brief, lin − BM cells were isolated using a lineage depletion kit (Miltenyi Biotech, Bergisch Gladbach, Germany) and cell sorting via FACSAria (BD Biosciences, San Jose, CA, USA). GFP transduction of HPCs and generation of the β-catenin-HPC line was described previously [16] . Briefly, the human β-catenin cDNA was cloned into the retroviral vector SFβ-91-IRES-eGFP, and recombinant VSV-G pseudotyped retroviruses were generated in the packaging cell line Phoenix-gp. β-Catenin-transduced cells stably expressed (N99%) hematopoietic stem cell markers Sca-1 and c-kit. Cells were cultured in IMDM containing 10% FCS, 2 mM L-Glutamine, 1% Penicillin-Streptomycin, 1 mM non-essential amino acids, 5 × 10 − 5 M 2-mercaptoethanol, 10 ng/ ml rm-IL-3 and 50 ng/ml rm-SCF (all from Cell Systems, St. Katharinen, Germany).
Experimental ischemia/reperfusion and cell injection
All animal studies were in compliance with the Guide for the Care and Use of Laboratory Animals as published by the U.S. National Institutes of Health (NIH Publication No. 85-23, revised 1996) and were approved by the local animal care committees. Ischemia/ reperfusion in mice and intraarterial injection of labeled cells were described previously [19] . Briefly, mice (age 10-12 weeks) were anesthetized and mechanically ventilated with isoflurane (1-2%). A left thoracotomy was performed after which the left anterior descending artery (LAD) was ligated with 8-0 Prolone with a slipknot, which was removed 120 min later. Control mice underwent a thoracotomy and an incision of the pericard solely (sham). The thoracic wall was closed in layers. After extubation, all animals were allowed to recover from surgery in an incubator (37°C). Twenty-four hours after I/R washed cells were suspended in 200 μl PBS and injected into the aortic root via the left carotid artery of recipient mice. Five weeks after I/R and cell application cardiac function and diameter were quantified by echocardiography, magnetic resonance imaging (MRI) or left heart catheterization.
For cell tracking cells were incubated in IMDM medium for 20 min at 37°C and finally labeled for 10 min at 37°C with 200 μM TAMRA [5-(and 6)-Carboxy-Tetramethylrhodamine Succinimidylester] (Molecular Probes) per 10 7 cells. Cell counts in the heart and in the spleen at 1 h and 1 week after infusion of β-catenin-HPCs were made on 6 μm sections and surface area of the myocardium or spleen on the section was measured by planimetry. The cell number was referred to a certain tissue volume (mm 3 ) [19] . Area at risk and early infarct size were assessed by Evan's blue and 2,3,5-triphenyltetrazolium chloride staining 48 h after I/R as described [20] . MI size after 5 weeks was determined in haematoxylin-and eosinstained sections using the Quantimet 500MC digital image analyzer as described previously [21] .
Transthoracic echocardiography, hemodynamic measurement and cine MRI
Echocardiography was performed in sedated mice (ketamine, 100 mg/kg, and xylazine, 1.25 mg/kg, i.p.) using a linear 15 MHz transducer (ATL HDI 5000 CV) as described [22] . In brief, short-axis Mmode images were recorded at the papillary muscle level in sedated mice using a linear 15 MHz transducer (ATL HDI 5000 CV). Fractional shortening (FS) was calculated as follows: FS [%] = [(LVEDD-LVESD)/ LVEDD] × 100 (LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter). LV ejection fraction (EF) was calculated as [(LVEDA-LVESA)/LVEDA] × 100, where LVEDA and LVESA denote LV end-diastolic and end-systolic areas, respectively. Hemodynamic measurements were performed in mice under anesthesia using a 1.4 F micromanometer conductance catheter (SPR-719; Millar Instruments, Houston, TX) as described [23] . In brief, mice were anaesthetized and mechanically ventilated with enflurane (3%), a bilateral vagotomy was performed, and the catheter was inserted in the LV cavity via the right carotid artery. Cine MRI was performed on a 7.05 T-Biospec (Bruker, Ettlingen, Germany) using an ECG-triggered fast gradient echo FLASH sequence as described previously [24] . Briefly, ten to 12 contiguous ventricular short-axis slices of 1-mm thickness were acquired to cover the entire heart. Imaging parameters were as follows: echo time TE = 1.6 ms; repetition time TR = 4.3 ms; field of view (30 mm 2 ); acquisition matrix, 128 × 128. The resulting in plane resolution was 120 × 120 μm. Analysis of end-systolic and enddiastolic LV volumes and LV mass was done using an operatorinteractive technique, and stroke volume and cardiac output were calculated, as previously described [25] .
Analysis of capillary density and immunostaining
Capillary density was determined 5 weeks after myocardial infarction in LV sections with transversely sectioned cardiomyocytes immunostained against Isolectin B4 (Vector) and counterstained with WGA and Hoechst 33258 (Sigma) as described previously [21] . In brief, the ratio of Isolectin B4 positive cells to the total number of nuclei (Hoechst stain) per field was calculated. Capillaries per high power fields were determined in LV sections double stained for Isolectin B4 and WGA. For each mouse, high power fields (400×; 200 μm × 200 μm; 8 fields per section of LV basis, middle part and apex; n = 4) with transversely sectioned cardiomyocytes were digitally recorded to calculate the number of capillaries per high power field.
TUNEL and caspase-3 assay
Apoptotic cardiomyocytes 48 h after MI were evaluated in serial paraffin sections by TUNEL assay with an ApopTag kit (Chemicon) in co-staining with an antibody against α-actinin (Sigma) as described previously [21] . Apoptotic morphology of nuclei was confirmed by counterstaining with DAPI. More than 20 tissue sections in each group were examined microscopically. Four fields each were selected in noninfarction and borderzone areas.
Caspase-3 + cardiomyocytes were evaluated 48 h after MI in serial paraffin sections. Staining was performed on 2 μm sections. Slides were dewaxed by xylene, rehydrated by graded alcohol and epitope retrieval was carried out in a microwave oven as has been described previously.
In brief, the slides were heated for 20 min (100°C) in 10 mM sodium citrate (pH 6.0) and transferred to tris-buffered saline (TBS). Sections were stained using the Shandon coverplate system in a Tecan Genesis Autostainer (Shandon, Frankfurt a.M., Germany; Tecan, Deisenhofen, Germany). Tissue peroxidase activity was quenched by incubation with 3% hydrogen peroxide for 10 min, followed by rinse with TRIS buffer and a repeated protein blocking. The anti-Caspase 3 antibody (clone ASP 175; Cell Signaling Technology, Danvers, MA) was applied in a dilution of 1:80. For detection, a standard ABC-method was used (ZytoChem Plus HRP, Zymed, San Francisco, CA). Counterstaining was done with Hemalaun, coverslips were mounted with Kaiser's glycerine (Merck, Darmstadt, Germany).
Transwell migration assay
1 × 10 5 bone marrow derived HPCs or β-catenin-HPCs in 100 μl RPMI medium were placed in the upper chamber of transwell cell culture inserts (5-μm pore size; Costar, Cambridge, MA). The lower chamber contained 600 μl RPMI medium supplemented with stromal cell-derived factor (SDF)-1 (100 ng/ml; Hölzel Diagnostika, Köln, Germany). Migration was carried out for 6 h at 37°C, 5% CO 2 and the number of migrated cells was determined in a Neubauer counting chamber using an inverted cell culture microscope (magnification, 100×; CKX31, Olympus, Hamburg, Germany).
Matrigel angiogenesis assay in vitro
Network formation by human umbilical cord endothelial cells (HUVECs) after 24 h was investigated in 48-well culture plates as reported recently [26] . Wells were coated with 50 μl growth factorreduced Matrigel (BD Biosciences, San Diego, CA) and seeded with 1.5 × 10
4 HUVECs and simultaneously with 0.5 × 10 4 or 1.5 × 10 4 β-catenin-HPCs using an inverted cell culture microscope (magnification, 40×; CKX31, Olympus, Hamburg, Germany) and a digital camera (C-5060, Olympus, Hamburg, Germany). Vascular endothelial growth factor (VEGF) was used as positive control (50 ng/ml, PeproTech, Rocky Hill, NJ). Closed circular structures (tube-like structures) were quantified per well.
Proliferation assay
HUVECs were cultured in gelatin coated 24-well plates in endothelial cell growth medium (EGM, PromoCell, Heidelberg, Germany) to ∼50% confluence and maintained over night in endothelial cell basal medium (EBM, PromoCell, Heidelberg, Germany). 0.5 × 10 4 or 1.5 × 10 4 β-cateninHPCs were seeded on transwell cell culture inserts (0.4-μm pore size; Costar, Cambridge, MA) and kept with HUVECs in co-culture. Cell proliferation was measured on the basis of DNA synthesis over 16 h by 5-bromo-2′-deoxyuride (BrdU) incorporation with a commercial colorimetric quantification kit (Roche, Mannheim, Germany) according to the manufacturer's protocol. The amount of reaction product was determined by measuring the absorbance at 450 nm using a plate reader (Fluorostar Galaxy, BMG Lab Technology, Helsinki, Finland). Vascular endothelial growth factor (VEGF) was used as positive control (50 ng/ml, PeproTech, Rocky Hill, NJ).
2.6.3. Enzyme-linked immunosordent assay (ELISA) 5×10 6 β-catenin-HPCs were cultured for 12 h in 10 ml IMDM without any supplements. Conditioned medium from independent cultures were analyzed for VEGF (VEGF-A) levels using a commercial ELISA (RayBiotech, Norcross, GA) according to the manufacturer's protocol and a plate reader (μQuant, BIO-TEK, Bad Friedrichshall, Germany).
Statistical analysis
Data are presented as mean ± SD. Differences between groups were analyzed by one-way ANOVA followed by Scheffe Post Hoc or Least Significant Difference (LSD) Post Hoc test, which was based on significant P-values in the ANOVA analysis. A P-value b0.05 was considered statistically significant.
Results
Transplantation of β-catenin-HPCs after I/R improves cardiac function in a threshold-dependent manner
Within the whole study period there was no difference in mortality between HPC treated animals and control treated animals: Sham (2/ 28), Saline (7/53), GFP-HPCs (1/11), β-catenin-HPCs Furthermore, invasive hemodynamic measurements demonstrated that cardiac output, +dP/dt max (maximal rate of pressure rise), −dP/dt max (maximal rate of pressure fall) and ejection fraction were significantly improved after HD β-catenin-HPC treatment (⁎P b 0.05, # P b 0.01, Figs. 3A, B, n = 8-12).
HPCs show a transient myocardial engraftment after intraarterial delivery
The migratory capacity of β-catenin-HPC was not altered compared to freshly isolated HPC (Fig. 4A) . To follow the fate of the transplanted cells, β-catenin-HPCs (1 × 10 7 , n = 8 each) were labeled with TAMRA before intraarterial transcatheter injection and cell homing was analyzed by fluorescence microscopy. TAMRA + cells were abundant in the myocardium at 1 h after delivery of 1 × 10 7 β-catenin-HPCs (n =4, Fig.   4B ), but were not detected after 1 week (n =4, Fig. 4B ). In contrast, a substantial number of TAMRA + cells were identified in the spleen after 1 h and this number increased robustly 1 week after cell transplantation ( Fig. 4B) , suggesting redistribution of HPCs to the spleen as part of the hematopoietic compartment. The TAMRA + cells detected in the myocardium were small, suggesting that the transplanted cells retained morphological characteristics of hematopoietic cells.
Transplantation of β-catenin-HPCs reduces infarct size
The effect of cell treatment on infarct size was determined 5 weeks after I/R. While LD treatment had no influence on infarct size, HD treatment with GFP-HPCs (1× 10 7 cells, ⁎Pb 0.05) or β-catenin-HPCs (1× 10 7 cells, # Pb 0.01) reduced infarct size significantly compared to saline control. In addition, the effect of HD β-catenin-HPC treatment on infarct size was significantly better than GFP-HPC treatment (⁎Pb 0.05, Fig. 4C ).
To determine early protective effects of β-catenin-HPCs on infarct size hearts were analyzed 48 h after I/R. The size of the area at risk during left coronary occlusion was comparable in β-catenin-HPCs (n = 7) and saline-injected (n = 6) hearts. However, infarct size was significantly smaller in β-catenin-HPC treated hearts (⁎P b 0.05, Fig.  4D ), indicating that the protective effect of β-catenin-HPCs on infarct size is initiated early after MI.
Transplantation of β-catenin-HPCs reduces myocardial apoptosis
Smaller infarct size after I/R in animals treated with HD β-cateninHPCs was associated with reduced apoptosis in cardiac cells in the borderzone reperfused area, yielding a 48% reduction of TUNEL + cells 0.01, Fig. 6B ). To analyze the underlying potential paracrine mechanism, secretion of VEGF a major angiogenic factor from β-catenin-HPCs was determined by ELISA. Conditioned medium of β-catenin-HPCs contained detectable amounts of VEGF-A (23.0 ± 11.6 pg/ml, Fig. 6C ).
Capillary density in the infarct border zone was significantly increased after HD β-catenin-HPC treatment compared to control treatment (capillaries/cardiomyocytes: β-catenin-HPCs 1.08 ± 0.11 vs. saline 0.91 ± 0.12, # P b 0.01). In the remote myocardium, there was no difference between these groups (1.00 ± 0.13 vs. 0.94 ± 0.17; P = n.s., Fig. 6D ).
Discussion
Although bone marrow cell therapy appears to provide beneficial effects post MI in experimental and clinical studies, major issues need To analyze the influence of cell dose on therapeutic efficacy we transplanted β-catenin-HPCs after I/R and compared the effects of a LD vs. a HD cell strategy 5 weeks after MI. LD cell therapy did not decrease infarct size and had only moderate effects on LV remodeling post MI, i.e. LVEDD and LVESD. In contrast, HD treatment decreased infarct size, improved LV function and improved LV remodeling compared to saline and LD treatment, indicating a threshold-dependent effect of HPC in myocardial cell therapy post MI. The protective effect of HD treatment on EF, LVESD and LVEDD was confirmed by MRT and further emphasized by invasive measurements, which showed increased cardiac output, cardiac contractility and relaxation after HD cell therapy compared to saline controls.
Cell dosage requirements of HPCs might limit the efficacy of bone marrow cell therapy. For example, in the ASTAMI trial, the median number of mononuclear cells injected was 68 × 10 6 , and the median number of CD34 + cells was 0.7 × 10 6 . There were no significant differences between the BMC and control group in changes in LVEF, end-diastolic volume, or infarct size [12] . In the BOOST trial, the average number of mononuclear BM cells was 24.6 × 10 8 , and the number of CD34 + cells was 9.5 × 10
6
. Six months after randomisation, global LVEF increased from 50.0% to 56.7% (P = 0.0026) [7] . In the TOPCARE-AMI trial, the average number of mononuclear BM cells was 24.5 × 10 7 , and the number of CD34 + cells was 7 × 10 6 . In patients receiving progenitor cells, global LVEF increased from 51.6% to 60.1% (P = 0.003) [8] . To treat a patient of 80 kg with a HD cell strategy as described here (1 × 10 7 cells/25 g) would require 32 × 10 9 CD34 + cells (adjusted to body weight), which exceeds the number of HPCs used in clinical trials by a factor of ∼ 3000 [7, 27] . Our results suggest that techniques allowing rapid ex vivo HPC expansion may improve cellbased clinical treatment regimens.
To address the therapeutic effects of HPC modification we treated mice with a HD treatment regimen and compared GFPtransduced-HPCs with β-catenin-transduced HPCs. Control-HPCs had moderate, but significantly, improved LV remodeling and LV FS. However, β-catenin-HPC treatment resulted in significant improvement of cardiac dimension and function over saline and control-HPCs. These observations suggest a therapeutic potential of β-catenin modification of HPCs. However, uncontrolled nuclear accumulation of β-catenin can cause developmental defects and tumorigenesis in the adult organism. For example, mutations in β-catenin and the GSK-3/APC/Axin complex, which regulates proteasome-mediated degradation of β-catenin, have also been found in sporadic colon cancers and a large variety of other tumor types [28] . As one alternative approach this carcinogenic risk could be reduced by employing inducible vector systems in the future, facilitating a specific and tightly regulated controlled expression of β-catenin. Our previous study indicated that ectopic expression of β-catenin provides a reproducible tool for establishing HPC lines without evidence of malignant transformation and with responsiveness to external stimuli [16] .
To address the potential mechanisms by which HPCs improved cardiac function we evaluated long-term engraftment, myocardial apoptosis and angiogenesis. HPCs injected by a transcatheter, intraarterial approach did not show long-term myocardial engraftment (N24 h), but were readily detected in hematopoietic organs, such as the spleen, after longer time intervals. In addition, β-catenin-HPCs did not show migratory impairment in vitro compared to isolated HPCs. Although our results do not formally exclude transdifferentiation of HPCs into myocytes or endothelial cells, they support previous reports showing only transient myocardial homing of HPC after MI when cells were given by intraarterial route [19, 29] . However, the current study was not designed to address the precise timing of cell administration, because we opted for a delayed cell treatment (24 h post I/R) to resemble closely the clinical setting in which cell-based therapy is performed a few days after the primary event.
In fact, the present observations are consistent with a paracrine mechanism of action. Paracrine factors released by stem and progenitor cells may stimulate cardiac angiogenesis and inhibit cardiac apoptosis. Previous studies reported that graft stem cells can secrete several important survival factors, such as vascular endothelial growth factor (VEGF), stromal cell-derived factor (SDF), basic fibroblast growth factor (bFGF), and insulin-like growth factor (IGF), which protect or salvage endangered ischemic myocardium [30] . Consistent with this hypothesis we observed increased capillary density and reduced myocardial apoptosis in the infarct border zone. Of note, tube formation in vitro was enhanced by β-catenin-HPCs coculture in a threshold-dependent manner. Furthermore, condition medium from β-catenin-HPCs enhanced tube formation in vitro (Templin, Grote et al., unpublished observation). Similarly, endothelial cell proliferation in vitro was significantly enhanced when co-cultured with β-catenin-HPCs in a threshold-dependent manner. Since coculture experiments were performed without any cell-to-cell contact paracrine factors must be involved. This is further supported by the detection of the major angiogenic factor VEGF in the conditioned medium of β-catenin-HPCs.
Our current study was not designed to investigate other potential indirect mechanisms that might improve cardiac function in the infarcted heart. Signaling molecules reported to be released by candidate cell types are known to mediate multiple potentially beneficial effects, including effects on cardiomyocyte metabolism, e.g. IGF-1 [31] , or modulation of inotropy by facotors such as IFG-1 [32] , bFGF [33, 34] , or IL-1β [35, 36] . Benefits could also be produced by modulation of extracellular matrix (ECM) homeostasis by (a) reducing proteolysis of the heart's existing ECM and preventing ventricular dilation; (b) hastening the formation of scar tissue, thereby halting ventricular dilation sooner; (c) reducing fibrosis in the noninfarcted region, thereby increasing compliance and diastolic function [37] . In this aspect, β-catenin could be one potential candidate in the healing process after MI by promoting survival and cell cycle not only in cardiomyocytes but also in cardiac fibroblasts with its differentiation into myofibroblasts [38] . A final potential mechanism of action by which exogenous cell therapies may improve function in recently infarcted hearts is by promoting repair by endogenous progenitor cells, e.g. proliferation of resident stem cells and recruitment of non-resident cells. In summary, only high-dose β-catenin-HPC transplantation caused a reduction in MI size, enhanced angiogenesis, and promoted antiapoptotic effects, associated with improvement of cardiac function.
Our data are consistent with the notion that the beneficial effects of β-catenin-HPCs are, at least in part, attributable to protection of ischemic myocardium. Thus, our study suggests that ex vivo expansion of HPCs may be an attractive therapeutic option. Indeed, such an approach utilizing human HSCs or HPCs may yield unlimited cell quantities for clinical application. 
